{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:02:15Z","timestamp":1777561335078,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>POEMS syndrome is a rare multisystem disease secondary to plasma cell neoplasm. Due to its rarity, there are no internationally agreed treatment standards, with very limited data to guide management in the relapse setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We describe a 51-year-old woman with initially presented with fatigue, anorexia, nausea, abdominal distension, and edema of the face and both lower limbs, who was diagnosed with POEMS syndrome accompanied with Raynaud\u2019s phenomenon and cardiac involvement. After multiple lines of treatment, including bortezomib, cyclophosphamide, and dexamethasone (VCD), ixazomib, and daratumumab along with dexamethasone (DD), her clinical and laboratory features, and cardiovascular system continued to deteriorate. Then we started carfilzomib and dexamethasone, and the patient achieved a complete response. She did not develop significant cardiac toxicity and peripheral neuropathy. A total of 4 cycles of carfilzomib and dexamethasone were administered monthly, followed by autologous stem cell transplantation (ASCT). After 4 months of follow-up, a complete remission persists, and no significant complications were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report on the first case of relapsed\/refractory POEMS syndrome who received carfilzomib and dexamethasone, and achieved very good remission. Carfilzomib may be a safe and effective treatment option for patients with relapsed\/refractory POEMS syndrome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1570981","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:45Z","timestamp":1749187425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with carfilzomib and dexamethasone for relapsed\/refractory POEMS syndrome: a case report and review of literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuang","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlaa021","article-title":"Skin and nerve neovascularization in POEMS syndrome: insights from a small cohort","volume":"79","author":"Guibert","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.27","article-title":"Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome","volume":"31","author":"Li","year":"2017","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.168","article-title":"Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome","volume":"31","author":"Wang","year":"2017","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2021.10.007","article-title":"POEMS syndrome: real world experience in diagnosis and systemic therapy - 108 patients multicenter analysis","volume":"22","author":"Jurczyszyn","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.344","article-title":"Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment","volume":"30","author":"Kourelis","year":"2016","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v200.2","article-title":"Evidence-based medical treatment of POEMS syndrome","volume":"200","author":"Khwaja","year":"2023","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.v39.1","article-title":"A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma","volume":"39","author":"Rocchi","year":"2021","journal-title":"Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2013.161.issue-3","article-title":"New advances in the diagnosis and treatment of POEMS syndrome","volume":"161","author":"Li","year":"2013","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41927-022-00258-y","article-title":"Raynaud\u2019s phenomenon and positive antinuclear antibodies as first manifestation of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes): a case report","volume":"6","author":"Torres-Saavedra","year":"2022","journal-title":"BMC Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000486","article-title":"Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome","volume":"5","author":"Pihan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2833","article-title":"Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide","volume":"49","author":"Inoue","year":"2010","journal-title":"Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.38.877","article-title":"Cardiomyopathy in a case of Crow-Fukase syndrome","volume":"38","author":"Shimizu","year":"1997","journal-title":"Jpn Heart J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.40.726","article-title":"Crow-Fukase syndrome with ischemic cardiomyopathy","volume":"40","author":"Ichikawa","year":"2001","journal-title":"Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.556","article-title":"Crow-Fukase syndrome associated with pulmonary hypertension","volume":"32","author":"Iwasaki","year":"1993","journal-title":"Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"ytab504","DOI":"10.1093\/ehjcr\/ytab504","article-title":"POEMS syndrome causing left ventricular hypertrophy, myocardial dysfunction, and pericardial effusion: a case report","volume":"6","author":"Wang","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.21037\/atm-21-1071","article-title":"Congestive heart failure associated with POEMS syndrome that was adequately distinguished from cardiac amyloidosis: a case report and literature review","volume":"9","author":"Hagiwara","year":"2021","journal-title":"Ann Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.9256","article-title":"Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome","volume":"52","author":"Yokokawa","year":"2013","journal-title":"Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304874","article-title":"Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome","volume":"84","author":"Sekiguchi","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000786","article-title":"Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma","volume":"6","author":"Sonneveld","year":"2022","journal-title":"Hemasphere"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0428-7","article-title":"Carfilzomib triple combination therapy: A review in relapsed multiple myeloma","volume":"11","author":"Hoy","year":"2016","journal-title":"Target Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.07.006","article-title":"Heart failure with carfilzomib in patients with multiple myeloma: A meta-analysis of randomized controlled trials","volume":"27","author":"Rahman","year":"2021","journal-title":"J Card Fail"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1570981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:45Z","timestamp":1749187425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1570981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1570981"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1570981","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1570981"}}